Changes in serum Sestrin2 and Omentin-1 levels in patients with acute cerebral hemorrhage and their correlation with the degree of neurological deficit and prognosis

Zhou Yifan; Yan Yijiu; Wang Changzhou; Wang Linfeng; Li Zhonglin

doi:10.3969/j.issn.1671-6450.2024.09.005

Abstract：Objective To investigate the changes of serum Sestrin2 and Omentin-1 levels in patients with acute cerebral hemorrhage(ACH)and their correlation with the degree of neurological deficit and prognosis.Methods One hun-dred and fifty-three ACH patients admitted to the Department of Neurosurgery of the Affiliated Hospital of Xuzhou Medical University from March 2021 to October 2023 were selected as the ACH group and 78 cases of those who had health check-ups during the same period were selected as the healthy control group.ACH patients were divided into mild deficit sub-group of 52 cases,moderate deficit subgroup of 61 cases,and severe deficit subgroup of 40 cases according to the degree of neurological deficit.The ACH patients were divided into poor prognosis subgroup(41 cases)and good prognosis sub-group(112 cases)according to their prognosis at 3 month follow up.Enzyme linked immunosorbent assay was used to de-tect serum Sestrin2 and Omentin-1 levels;Spearman method was used to analyze the correlation between NIHSS score and serum levels of Sestrin2 and Omentin-1 in ACH patients;Logistic regression model was used to analyze the influencing fac-tors of poor prognosis in ACH patients;and ROC curves were plotted to evaluate the serum Sestrin2,Omentin-1 levels to predict the value of poor prognosis in ACH patients.Results Compared with the healthy control group,the serum Sestrin2 level in the ACH group increased,while the Omentin-1 level decreased(t/P=9.721/＜0.001,11.375/＜0.001).Serum Sestrin2 levels increased sequentially in the mild,moderate,and severe deficit subgroups,while Omentin-1 levels decreased sequen-tially(F/P=136.537/＜0.001,297.024/＜0.001).Compared with the poor prognosis subgroup,the good prognosis subgroup had smaller hematoma volume,lower NIHSS score,lower serum Sestrin2 level,and higher Omentin-1 level,with statistically significant differences(t/P=5.636/＜0.001,6.440/＜0.001,6.657/＜0.001,6.104/＜0.001).The NIHSS score of ACH patients was negatively correlated and positively correlated with serum levels of Sestrin2 and Omentin-1,respectively(r/P=-0.811/＜0.001,0.829/＜0.001);After a 3 month follow up,the incidence of adverse prognosis in 153 ACH patients was 26.80％ .The independent risk factors for poor prognosis in ACH patients were increased hematoma volume,elevated NIHSS score,and elevated Sestrin2,the independent protective factor was elevated Omentin-1[OR(95％ CI)=1.219(1.093-1.360),1.164(1.079-1255),1.647(1218-2227),0.976(0.963-0.989)];The serum levels of Sestrin2 and Omentin-1,as well as the area un-der the curve(AUC)of their combined prediction of adverse prognosis in ACH patients,were 0.795,0.771,and 0.870,respec-tively.The AUC of their combined prediction of adverse prognosis in ACH patients was the highest(Z=2.493,3.181,P=0.013,0.002).Conclusion Elevated serum Sestrin2 levels and decreased serum Omentin-1 levels in ACH patients are closely related to the severity of neurological deficits and poor prognosis.The combination of serum Sestrin2 and Omentin-1 levels has high value in predicting poor prognosis.